Literature DB >> 14969388

Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF.

Jason M Hodge1, Mark A Kirkland, Cathy J Aitken, Caryll M Waugh, Damian E Myers, Carolina M Lopez, Brendan E Adams, Geoffrey C Nicholson.   

Abstract

UNLABELLED: Human osteoclasts can be efficiently generated in vitro from cord blood mononuclear cells and derived CFU-GM colonies. However, CFU-M colonies are poorly osteoclastogenic. Short-term (2-48 h) treatment with GM-CSF stimulates osteoclast formation by proliferating precursors, whereas longer exposure favors dendritic cell formation.
INTRODUCTION: Osteoclasts (OC) differentiate from cells of the myelomonocytic lineage under the influence of macrophage-colony stimulating factor (M-CSF) and RANKL. However, cells of this lineage can also differentiate to macrophages and dendritic cells (DC) depending on the cytokine environment. The aims of this study were to develop an efficient human osteoclastogenesis model and to investigate the roles of granulocyte macrophage-colony stimulating factor (GM-CSF) and M-CSF in human OC differentiation.
MATERIALS AND METHODS: A human osteoclastogenesis model, using as precursors colony forming unit-granulocyte macrophage (CFU-GM) colonies generated from umbilical cord mononuclear cells cultured in methylcellulose with GM-CSF, interleukin (IL)-3 and stem cell factor (SCF), has been developed. CFU-GM, colony forming unit-macrophage (CFU-M), or mixed colonies were cultured on dentine with soluble RANKL (sRANKL) and human M-CSF with and without GM-CSF. Major endpoints were OC number, dentine resorption, and CD1a+ DC clusters.
RESULTS: Osteoclast generation from CFU-GM and mixed colonies treated with M-CSF and sRANKL for 7-14 days was highly efficient, but CFU-M colonies were poorly osteoclastogenic under these conditions. Pretreatment of precursors with M-CSF for 7 or 14 days maintained the precursor pool, but OCs were smaller and resorption was reduced. The effect of GM-CSF treatment was biphasic, depending on the timing and duration of exposure. Short-term treatment (2-48 h) at the beginning of the culture stimulated cell proliferation and enhanced OC formation up to 100%, independent of sRANKL. Longer-term GM-CSF treatment in the presence of sRANKL, however, inhibited OC generation with the formation of extensive CD1a+ DC clusters, accompanied by downregulation of c-Fos mRNA. Delaying the addition of GM-CSF resulted in progressively less inhibition of osteoclastogenesis.
CONCLUSIONS: Human CFU-GM, but not CFU-M, progenitors have high osteoclastogenic potential. GM-CSF plays an important role in osteoclastogenesis and has a biphasic effect: Short-term treatment potentiates OC differentiation by proliferating precursors, but persistent exposure favors DC formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14969388     DOI: 10.1359/JBMR.0301232

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  20 in total

1.  Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.

Authors:  J Costa-Rodrigues; A Fernandes; M H Fernandes
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

2.  Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.

Authors:  Jinlu Dai; Yi Lu; Chunyan Yu; Jill M Keller; Atsushi Mizokami; Jian Zhang; Evan T Keller
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

3.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

4.  Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.

Authors:  D Grcević; I K Lukić; N Kovacić; S Ivcević; V Katavić; A Marusić
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

5.  Nmp4/CIZ suppresses the parathyroid hormone anabolic window by restricting mesenchymal stem cell and osteoprogenitor frequency.

Authors:  Yongzheng He; Paul Childress; Mark Hood; Marta Alvarez; Melissa A Kacena; Michael Hanlon; Bryce McKee; Joseph P Bidwell; Feng-Chun Yang
Journal:  Stem Cells Dev       Date:  2012-09-14       Impact factor: 3.272

Review 6.  Regulation of Embryonic and Postnatal Development by the CSF-1 Receptor.

Authors:  Violeta Chitu; E Richard Stanley
Journal:  Curr Top Dev Biol       Date:  2016-12-01       Impact factor: 4.897

7.  Influence of receptor activator of nuclear factor (NF)-kappaB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fetal calf serum on human osteoclast formation and activity.

Authors:  Ludwika Kreja; Astrid Liedert; Carla Schmidt; Lutz Claes; Anita Ignatius
Journal:  J Mol Histol       Date:  2007-06-19       Impact factor: 2.611

8.  Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.

Authors:  Tiffany J Dickerson; Erika Suzuki; Catherine Stanecki; Hyun-Seock Shin; Hong Qui; Iannis E Adamopoulos
Journal:  J Autoimmun       Date:  2012-08-03       Impact factor: 7.094

9.  Genetic background influences fluoride's effects on osteoclastogenesis.

Authors:  Dong Yan; Aruna Gurumurthy; Maggie Wright; T Wayne Pfeiler; Elizabeth G Loboa; Eric T Everett
Journal:  Bone       Date:  2007-08-08       Impact factor: 4.398

10.  DAP12 overexpression induces osteopenia and impaired early hematopoiesis.

Authors:  Geneviève Despars; Subramanya N M Pandruvada; Adrienne Anginot; Chantal Domenget; Pierre Jurdic; Marlène Mazzorana
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.